Literature DB >> 24079880

Preoperative B-type natriuretic peptide levels are associated with outcome after total cavopulmonary connection (Fontan).

Monique Radman1, Roberta L Keller2, Peter Oishi1, Sanjeev A Datar2, Kari Wellnitz2, Anthony Azakie3, Frank Hanley4, Danton Char5, Jong-Hau Hsu6, Rambod Amrinovin7, Ian Adatia8, Jeffrey R Fineman9.   

Abstract

OBJECTIVE: The study objective was to determine the association between preoperative B-type natriuretic peptide levels and outcome after total cavopulmonary connection. Surgical palliation of univentricular cardiac defects requires a series of staged operations, ending in a total cavopulmonary connection. Although outcomes have improved, there remains an unpredictable risk of early total cavopulmonary connection takedown. The prediction of adverse postoperative outcomes is imprecise, despite an extensive preoperative evaluation.
METHODS: We prospectively enrolled 50 patients undergoing total cavopulmonary connection. We collected preoperative clinical data, preoperative plasma B-type natriuretic peptide levels, and postoperative outcomes, including the incidence of an adverse outcome within 1 year of surgery (defined as death, total cavopulmonary connection takedown, or the need for cardiac transplantation).
RESULTS: The mean age of patients was 4.7 years (standard deviation, 2.1 years). The median (interquartile range) preoperative B-type natriuretic peptide levels were higher in patients who required total cavopulmonary connection takedown and early postoperative mechanical cardiac support (n = 3; median, 55; interquartile range, 42-121) compared with those with a good outcome (n = 47; median, 11; interquartile range, 5-17) (P < .05). A preoperative B-type natriuretic peptide level of 40 pg/mL or greater was highly associated with the need for total cavopulmonary connection takedown (sensitivity, 100%; specificity, 93%; P < .05), yielding a positive predictive value of 50% and a negative predictive value of 100%. Higher preoperative B-type natriuretic peptide levels also were associated with longer intensive care unit length of stay, longer hospital length of stay, and increased incidence of low cardiac output syndrome (P < .05).
CONCLUSIONS: Preoperative B-type natriuretic peptide blood levels are uniquely associated with the need for mechanical support early after total cavopulmonary connection and total cavopulmonary connection takedown, and thus may provide important information in addition to the standard preoperative assessment.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24079880      PMCID: PMC3968237          DOI: 10.1016/j.jtcvs.2013.08.009

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  26 in total

Review 1.  Natriuretic peptides.

Authors:  E R Levin; D G Gardner; W K Samson
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

2.  18 years of the Fontan operation at a single institution: results from 771 consecutive patients.

Authors:  Lindsay S Rogers; Andrew C Glatz; Chitra Ravishankar; Thomas L Spray; Susan C Nicolson; Jack Rychik; Christina Hayden Rush; J William Gaynor; David J Goldberg
Journal:  J Am Coll Cardiol       Date:  2012-07-18       Impact factor: 24.094

3.  Fontan operation in five hundred consecutive patients: factors influencing early and late outcome.

Authors:  T L Gentles; J E Mayer; K Gauvreau; J W Newburger; J E Lock; J P Kupferschmid; J Burnett; R A Jonas; A R Castañeda; G Wernovsky
Journal:  J Thorac Cardiovasc Surg       Date:  1997-09       Impact factor: 5.209

4.  A new natriuretic peptide in porcine brain.

Authors:  T Sudoh; K Kangawa; N Minamino; H Matsuo
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

5.  Surgical repair of tricuspid atresia.

Authors:  F Fontan; E Baudet
Journal:  Thorax       Date:  1971-05       Impact factor: 9.139

6.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.

Authors:  Q Dao; P Krishnaswamy; R Kazanegra; A Harrison; R Amirnovin; L Lenert; P Clopton; J Alberto; P Hlavin; A S Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.

Authors:  Timothy M Hoffman; Gil Wernovsky; Andrew M Atz; Thomas J Kulik; David P Nelson; Anthony C Chang; James M Bailey; Akbar Akbary; John F Kocsis; Raymond Kaczmarek; Thomas L Spray; David L Wessel
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

8.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Authors:  Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

9.  Normal values of B type natriuretic peptide in infants, children, and adolescents.

Authors:  A Koch; H Singer
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

10.  Factors influencing survival in patients undergoing the bidirectional Glenn anastomosis.

Authors:  J C Alejos; R G Williams; J M Jarmakani; A J Galindo; J B Isabel-Jones; D Drinkwater; H Laks; S Kaplan
Journal:  Am J Cardiol       Date:  1995-05-15       Impact factor: 2.778

View more
  1 in total

Review 1.  The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review.

Authors:  Briony F Hudson; Linda Jm Oostendorp; Bridget Candy; Victoria Vickerstaff; Louise Jones; Monica Lakhanpaul; Myra Bluebond-Langner; Paddy Stone
Journal:  Palliat Med       Date:  2016-09-08       Impact factor: 4.762

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.